These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 23630346)

  • 21. Trastuzumab (herceptin) targets gastric cancer stem cells characterized by CD90 phenotype.
    Jiang J; Zhang Y; Chuai S; Wang Z; Zheng D; Xu F; Zhang Y; Li C; Liang Y; Chen Z
    Oncogene; 2012 Feb; 31(6):671-82. PubMed ID: 21743497
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Overcoming trastuzumab resistance in HER2-overexpressing breast cancer cells by using a novel celecoxib-derived phosphoinositide-dependent kinase-1 inhibitor.
    Tseng PH; Wang YC; Weng SC; Weng JR; Chen CS; Brueggemeier RW; Shapiro CL; Chen CY; Dunn SE; Pollak M; Chen CS
    Mol Pharmacol; 2006 Nov; 70(5):1534-41. PubMed ID: 16887935
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Inhibition of the mTOR/S6K signal is necessary to enhance fluorouracil-induced apoptosis in gastric cancer cells with HER2 amplification.
    Tomioka H; Mukohara T; Kataoka Y; Ekyalongo RC; Funakoshi Y; Imai Y; Kiyota N; Fujiwara Y; Minami H
    Int J Oncol; 2012 Aug; 41(2):551-8. PubMed ID: 22614071
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Upregulation of mucin4 in ER-positive/HER2-overexpressing breast cancer xenografts with acquired resistance to endocrine and HER2-targeted therapies.
    Chen AC; Migliaccio I; Rimawi M; Lopez-Tarruella S; Creighton CJ; Massarweh S; Huang C; Wang YC; Batra SK; Gutierrez MC; Osborne CK; Schiff R
    Breast Cancer Res Treat; 2012 Jul; 134(2):583-93. PubMed ID: 22644656
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Lapatinib sensitivities of two novel trastuzumab-resistant HER2 gene-amplified gastric cancer cell lines.
    Oshima Y; Tanaka H; Murakami H; Ito Y; Furuya T; Kondo E; Kodera Y; Nakanishi H
    Gastric Cancer; 2014; 17(3):450-62. PubMed ID: 23948998
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Preclinical antitumor activity of the novel heat shock protein 90 inhibitor CH5164840 against human epidermal growth factor receptor 2 (HER2)-overexpressing cancers.
    Ono N; Yamazaki T; Nakanishi Y; Fujii T; Sakata K; Tachibana Y; Suda A; Hada K; Miura T; Sato S; Saitoh R; Nakano K; Tsukuda T; Mio T; Ishii N; Kondoh O; Aoki Y
    Cancer Sci; 2012 Feb; 103(2):342-9. PubMed ID: 22050138
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Trastuzumab and oxaliplatin exhibit a synergistic antitumor effect in HER2-postive gastric cancer cells.
    Ding X; Qu X; Fan Y; Che X; Qu J; Xu L; Liu J; Liu Y
    Anticancer Drugs; 2014 Mar; 25(3):315-22. PubMed ID: 24300914
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Suppression of tumor growth in human gastric cancer with HER2 overexpression by an anti-HER2 antibody in a murine model.
    Matsui Y; Inomata M; Tojigamori M; Sonoda K; Shiraishi N; Kitano S
    Int J Oncol; 2005 Sep; 27(3):681-5. PubMed ID: 16077916
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Antitumor activity of a combination of trastuzumab (Herceptin) and oral fluoropyrimidine S-1 on human epidermal growth factor receptor 2-overexpressing pancreatic cancer.
    Saeki H; Yanoma S; Takemiya S; Sugimasa Y; Akaike M; Yukawa N; Rino Y; Imada T
    Oncol Rep; 2007 Aug; 18(2):433-9. PubMed ID: 17611667
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Feasibility of tailored, selective and effective anticancer chemotherapy by direct injection of docetaxel-loaded immunoliposomes into Her2/neu positive gastric tumor xenografts.
    Yamamoto Y; Yoshida M; Sato M; Sato K; Kikuchi S; Sugishita H; Kuwabara J; Matsuno Y; Kojima Y; Morimoto M; Horiuchi A; Watanabe Y
    Int J Oncol; 2011 Jan; 38(1):33-9. PubMed ID: 21109923
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Preclinical study of prolonged administration of trastuzumab as combination therapy after disease progression during trastuzumab monotherapy.
    Fujimoto-Ouchi K; Sekiguchi F; Yamamoto K; Shirane M; Yamashita Y; Mori K
    Cancer Chemother Pharmacol; 2010 Jul; 66(2):269-76. PubMed ID: 19904537
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Mechanisms of disease: understanding resistance to HER2-targeted therapy in human breast cancer.
    Nahta R; Yu D; Hung MC; Hortobagyi GN; Esteva FJ
    Nat Clin Pract Oncol; 2006 May; 3(5):269-80. PubMed ID: 16683005
    [TBL] [Abstract][Full Text] [Related]  

  • 33. IL-6 induces MUC4 expression through gp130/STAT3 pathway in gastric cancer cell lines.
    Mejías-Luque R; Peiró S; Vincent A; Van Seuningen I; de Bolós C
    Biochim Biophys Acta; 2008 Oct; 1783(10):1728-36. PubMed ID: 18573283
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effect of MUC1 siRNA on drug resistance of gastric cancer cells to trastuzumab.
    Deng M; Jing DD; Meng XJ
    Asian Pac J Cancer Prev; 2013; 14(1):127-31. PubMed ID: 23534710
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effect of multikinase inhibitors on caspase-independent cell death and DNA damage in HER2-overexpressing breast cancer cells.
    Seoane S; Montero JC; Ocaña A; Pandiella A
    J Natl Cancer Inst; 2010 Sep; 102(18):1432-46. PubMed ID: 20811002
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A role for human MUC4 mucin gene, the ErbB2 ligand, as a target of TGF-beta in pancreatic carcinogenesis.
    Jonckheere N; Perrais M; Mariette C; Batra SK; Aubert JP; Pigny P; Van Seuningen I
    Oncogene; 2004 Jul; 23(34):5729-38. PubMed ID: 15184872
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Trastuzumab triggers phagocytic killing of high HER2 cancer cells in vitro and in vivo by interaction with Fcγ receptors on macrophages.
    Shi Y; Fan X; Deng H; Brezski RJ; Rycyzyn M; Jordan RE; Strohl WR; Zou Q; Zhang N; An Z
    J Immunol; 2015 May; 194(9):4379-86. PubMed ID: 25795760
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Trastuzumab enhances the anti-tumor effects of the histone deacetylase inhibitor sodium butyrate on a HER2-overexpressing breast cancer cell line.
    Chen W; Wei F; Xu J; Wang Y; Chen L; Wang J; Guan X
    Int J Mol Med; 2011 Dec; 28(6):985-91. PubMed ID: 21887460
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Nonclinical studies addressing the mechanism of action of trastuzumab (Herceptin).
    Sliwkowski MX; Lofgren JA; Lewis GD; Hotaling TE; Fendly BM; Fox JA
    Semin Oncol; 1999 Aug; 26(4 Suppl 12):60-70. PubMed ID: 10482195
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Transcriptional regulation of human mucin MUC4 by bile acids in oesophageal cancer cells is promoter-dependent and involves activation of the phosphatidylinositol 3-kinase signalling pathway.
    Mariette C; Perrais M; Leteurtre E; Jonckheere N; Hémon B; Pigny P; Batra S; Aubert JP; Triboulet JP; Van Seuningen I
    Biochem J; 2004 Feb; 377(Pt 3):701-8. PubMed ID: 14583090
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.